Checkpoint Therapeutics develops immunotherapy and targeted cancer treatments using a streamlined approach that accelerates drug development and commercialization. The company addresses the high costs and limited access to effective cancer therapies by providing potentially life-saving options at lower prices compared to traditional pharmaceutical companies.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The high cost and slow development timelines of traditional cancer therapies limit patient access to potentially life-saving treatments. Existing development processes often involve significant financial risk and lengthy clinical trials, delaying the availability of new drugs.
Solution
Checkpoint Therapeutics focuses on developing immunotherapy and targeted cancer treatments through a streamlined, "fast-follower" approach. This strategy aims to accelerate the development and commercialization of oncology drugs, providing effective treatment options at potentially lower prices compared to traditional pharmaceutical companies. By reducing development costs and timelines, Checkpoint Therapeutics seeks to expand patient access to innovative cancer therapies.
Target Audience
The primary target audience includes cancer patients, healthcare providers, and payers seeking effective and more affordable treatment options.
Features
- Streamlined drug development process to reduce time and cost
- Focus on immunotherapy and targeted therapies
- "Fast-follower" strategy to leverage existing research and development